C H Smorenburg1, S M de Groot2, A E van Leeuwen-Stok3, M E Hamaker4, A N Wymenga5, H de Graaf6, F E de Jongh7, J J Braun8, M Los9, E Maartense10, H van Tinteren11, J W R Nortier12, C Seynaeve13. 1. Department of Internal Medicine, Medical Center Alkmaar, Alkmaar. Electronic address: c.smorenburg@nki.nl. 2. Comprehensive Cancer Center the Netherlands, Amsterdam. 3. BOOG Study Center, Dutch Breast Cancer Research Group BOOG, Amsterdam. 4. Department of Geriatric Medicine, Diakonessenhuis, Utrecht. 5. Department of Internal Medicine, Medisch Spectrum Twente, Enschede. 6. Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden. 7. Department of Internal Medicine, Ikazia Hospital, Rotterdam. 8. Department of Internal Medicine, Vlietland Hospital, Schiedam. 9. Department of Internal Medicine, St. Antonius Hospital, Nieuwegein. 10. Department of Internal Medicine, Reinier de Graaf Hospital, Delft. 11. Biometrics Department, Netherlands Cancer Institute, Amsterdam. 12. Department of Medical Oncology, Leiden University Medical Center, Leiden. 13. Department of Medical Oncology, Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND: Prospective data on chemotherapy for elderly patients with metastatic breast cancer (MBC) remain scarce. We compared the efficacy and safety of first-line chemotherapy with pegylated liposomal doxorubicin (PLD) versus capecitabine in MBC patients aged ≥65 years in a multicentre, phase III trial. PATIENTS AND METHODS: Patients were randomized to six cycles of PLD (45 mg/m(2) every 4 weeks) or eight cycles of capecitabine (1000 mg/m(2) twice daily, day 1-14 every 3 weeks). RESULTS: The study enrolled 78 of the planned 154 patients and was closed prematurely due to slow accrual and supply problems of PLD. Many included patients were aged ≥75 years (54%) and vulnerable (≥1 geriatric condition: 71%). The median dose intensity was 85% for PLD and 84% for capecitabine, respectively. In both arms, the majority of patients completed at least 12 weeks of treatment (PLD 73%; capecitabine 74%). After a median follow-up of 39 months, 77 patients had progressed and 62 patients had died of MBC. Median progression-free survival was 5.6 versus 7.7 months (P = 0.11) for PLD and capecitabine, respectively. Median overall survival was 13.8 months for PLD and 16.8 months for capecitabine (P = 0.59). Both treatments were feasible, grade 3 toxicities consisting of fatigue (both arms: 13%), hand-foot syndrome (PLD: 10%; capecitabine: 16%), stomatitis (PLD: 10%; capecitabine: 3%), exanthema (PLD: 5%) and diarrhoea (PLD: 3%; capecitabine: 5%). Only 1 of 10 patients aged ≥80 years completed chemotherapy, while 3 and 6 patients discontinued treatment due to toxicity or progressive disease, respectively. CONCLUSION: Both PLD and capecitabine demonstrated comparable efficacy and acceptable tolerance as first-line single-agent chemotherapy in elderly patients with MBC, even in vulnerable patients or patients aged ≥75 years. However, patients aged ≥80 years were unlikely to complete chemotherapy successfully. CLINICAL TRIAL NUMBERS: EudraCT 2006-002046-10; ISRCTN 11114726; CKTO 2006-09; BOOG 2006-02.
BACKGROUND: Prospective data on chemotherapy for elderly patients with metastatic breast cancer (MBC) remain scarce. We compared the efficacy and safety of first-line chemotherapy with pegylated liposomal doxorubicin (PLD) versus capecitabine in MBC patients aged ≥65 years in a multicentre, phase III trial. PATIENTS AND METHODS: Patients were randomized to six cycles of PLD (45 mg/m(2) every 4 weeks) or eight cycles of capecitabine (1000 mg/m(2) twice daily, day 1-14 every 3 weeks). RESULTS: The study enrolled 78 of the planned 154 patients and was closed prematurely due to slow accrual and supply problems of PLD. Many included patients were aged ≥75 years (54%) and vulnerable (≥1 geriatric condition: 71%). The median dose intensity was 85% for PLD and 84% for capecitabine, respectively. In both arms, the majority of patients completed at least 12 weeks of treatment (PLD 73%; capecitabine 74%). After a median follow-up of 39 months, 77 patients had progressed and 62 patients had died of MBC. Median progression-free survival was 5.6 versus 7.7 months (P = 0.11) for PLD and capecitabine, respectively. Median overall survival was 13.8 months for PLD and 16.8 months for capecitabine (P = 0.59). Both treatments were feasible, grade 3 toxicities consisting of fatigue (both arms: 13%), hand-foot syndrome (PLD: 10%; capecitabine: 16%), stomatitis (PLD: 10%; capecitabine: 3%), exanthema (PLD: 5%) and diarrhoea (PLD: 3%; capecitabine: 5%). Only 1 of 10 patients aged ≥80 years completed chemotherapy, while 3 and 6 patients discontinued treatment due to toxicity or progressive disease, respectively. CONCLUSION: Both PLD and capecitabine demonstrated comparable efficacy and acceptable tolerance as first-line single-agent chemotherapy in elderly patients with MBC, even in vulnerable patients or patients aged ≥75 years. However, patients aged ≥80 years were unlikely to complete chemotherapy successfully. CLINICAL TRIAL NUMBERS: EudraCT 2006-002046-10; ISRCTN 11114726; CKTO 2006-09; BOOG 2006-02.
Entities:
Keywords:
capecitabine; elderly; geriatric; metastatic breast cancer; pegylated liposomal doxorubicin; phase III
Authors: Hans Wildiers; Murielle Mauer; Athanasios Pallis; Arti Hurria; Supriya G Mohile; Andrea Luciani; Giuseppe Curigliano; Martine Extermann; Stuart M Lichtman; Karla Ballman; Harvey Jay Cohen; Hyman Muss; Ulrich Wedding Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: F Cardoso; A Costa; L Norton; D Cameron; T Cufer; L Fallowfield; P Francis; J Gligorov; S Kyriakides; N Lin; O Pagani; E Senkus; C Thomssen; M Aapro; J Bergh; A Di Leo; N El Saghir; P A Ganz; K Gelmon; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; M Leadbeater; M Mayer; A Rodger; H Rugo; V Sacchini; G Sledge; L van't Veer; G Viale; I Krop; E Winer Journal: Breast Date: 2012-03-16 Impact factor: 4.380
Authors: J A Oshaughnessy; J Blum; V Moiseyenko; S E Jones; D Miles; D Bell; R Rosso; L Mauriac; B Osterwalder; H U Burger; S Laws Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: M E Hamaker; C Seynaeve; A N M Wymenga; H van Tinteren; J W R Nortier; E Maartense; H de Graaf; F E de Jongh; J J Braun; M Los; J G Schrama; A E van Leeuwen-Stok; S M de Groot; C H Smorenburg Journal: Breast Date: 2013-12-05 Impact factor: 4.380
Authors: O Feher; P Vodvarka; J Jassem; G Morack; S H Advani; K S Khoo; D C Doval; S Ermisch; D Roychowdhury; M A Miller; G von Minckwitz Journal: Ann Oncol Date: 2005-04-08 Impact factor: 32.976
Authors: M E Hamaker; C Seynaeve; J W R Nortier; M Wymenga; E Maartense; E Boven; A E van Leeuwen-Stok; S E de Rooij; B C van Munster; C H Smorenburg Journal: Breast Date: 2013-01-08 Impact factor: 4.380
Authors: F L Gerritse; H J Meulenbeld; J M L Roodhart; A M T van der Velden; R J B Blaisse; T J Smilde; Z Erjavec; R de Wit; M Los Journal: Eur J Cancer Date: 2013-07-09 Impact factor: 9.162
Authors: Ann H Partridge; R Bryan Rumble; Lisa A Carey; Steven E Come; Nancy E Davidson; Angelo Di Leo; Julie Gralow; Gabriel N Hortobagyi; Beverly Moy; Douglas Yee; Shelley B Brundage; Michael A Danso; Maggie Wilcox; Ian E Smith Journal: J Clin Oncol Date: 2014-09-02 Impact factor: 44.544
Authors: Bhavana Pothuri; Allison L Brodsky; Joseph A Sparano; Stephanie V Blank; Mimi Kim; Dawn L Hershman; Amy Tiersten; Brian F Kiesel; Jan H Beumer; Leonard Liebes; Franco Muggia Journal: Cancer Chemother Pharmacol Date: 2020-02-13 Impact factor: 3.333
Authors: Siao-Nge Hoon; Peter Kh Lau; Alison M White; Max K Bulsara; Patricia D Banks; Andrew D Redfern Journal: Cochrane Database Syst Rev Date: 2021-05-26